Posted On: 08/22/2016 12:57:54 PM
Post# of 83
Mcap $49 M /Cash till mid 2018/ 2 NDA Submissions in early 1Q / Multiple Partner Deals imminent
THIS STOCK IS A LIFETIME OPPORTUNITY
IGXT has a ridiculous Market Cap of US$49 Million which is a Big Joke for a Company with such a MEGA Product Pipeline , this Co has everything to be the next 10 Bagger minimum .GL
Intelgenx (IGXT) (IGX.V)
Market Cap: $49 Million
Cash: $7.1 Million
Burn-Rate: ~$400k per Quarter
Shares Out : 63.6 Million
Upcoming Milestones :
"Continued late-stage discussions with global pharmaceutical companies for multiple products with the potential goal of concluding a definitive agreement to be finalized in the third quarter of 2016"
Product :Indicated for Opioid Dependence
•Awaiting FDA approval
•According to IMS data, the oral film market for opioid dependence was worth more than $1.4B US in 2014.
Product :Rizaport (Migraine)
•European Mktg Approval–November 2015
•Planned USA submission to FDA Q1/2017
•Expected USA launch Q2/2017
Product :Tadalafil (Erectile Dysfunction)
•505(b)(2) USA NDA submission in Q1/2017
•Expected USA launch Q4/2017
THIS STOCK IS A LIFETIME OPPORTUNITY
IGXT has a ridiculous Market Cap of US$49 Million which is a Big Joke for a Company with such a MEGA Product Pipeline , this Co has everything to be the next 10 Bagger minimum .GL
Intelgenx (IGXT) (IGX.V)
Market Cap: $49 Million
Cash: $7.1 Million
Burn-Rate: ~$400k per Quarter
Shares Out : 63.6 Million
Upcoming Milestones :
"Continued late-stage discussions with global pharmaceutical companies for multiple products with the potential goal of concluding a definitive agreement to be finalized in the third quarter of 2016"
Product :Indicated for Opioid Dependence
•Awaiting FDA approval
•According to IMS data, the oral film market for opioid dependence was worth more than $1.4B US in 2014.
Product :Rizaport (Migraine)
•European Mktg Approval–November 2015
•Planned USA submission to FDA Q1/2017
•Expected USA launch Q2/2017
Product :Tadalafil (Erectile Dysfunction)
•505(b)(2) USA NDA submission in Q1/2017
•Expected USA launch Q4/2017
(0)
(0)
